A Phase 3 interventional study of Investigational live attenuated varicella vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 2 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-09.
Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 12 in phase 3, and was the 27th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:
SK Bioscience Co., Ltd. · Sites in Honduras, Philippines, Korea, Republic of and 1 more country
Ages 12 mo–12 yrs · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages up to 18
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 8–16 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 1–17 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in Vietnam
Ages 1–12 · Healthy volunteers
By country, each count listing its studies:
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 2 Years to 6 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 14 · Phase 4 14
First in 1998; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,193 is above the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 404 across the 36 interventional studies. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sinovac (Dalian) Vaccine Technology Co., Ltd., one of the names counted as Sinovac Biotech Co., Ltd. Under that name alone:
Sinovac (Dalian) Vaccine Technology Co., Ltd. is the lead sponsor of 20 studies on the registry; 7 are open to participants now.
17 studies in Chickenpox by Sinovac Biotech Co., Ltd: 7 open now, 7 under way, 3 of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 17 studies in Chickenpox by Sinovac Biotech Co., Ltd, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 3, and was the 6th registered.
Sinovac Biotech Co., Ltd’s Chickenpox studies by the year they started, since 2014.
1 of the studies testing Chickenpox Vaccine in Chickenpox that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07415252Phase 3SK Bioscience Co., Ltd.SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | 2027-02-13 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sinovac Biotech Co., Ltd’s 17 in Chickenpox:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose primary immunization of live attenuated varicella vaccine on different time points ,and the safety and immunogenicity after the booster immunization
This study is an open-labelled phase Ⅲ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.A total of 1195 subjects who received vaccine in the phase Ⅲ lot-consistency clinical trial were be enrolled .All subjects except C0243 and C0556 were divided into 3 groups according to the order of study number.Subjects in 3 groups received a booster immunization of live attenuated varicella vaccines 1 year,2 years and 3 years after primary immunization,respectively.About 3.0ml of venous blood was collected from each enrolled subject at pre-booster immunization,30 days after booster immunization and the serum was separated for neutralizing antibody detection.The antibody levels were used to evaluate the immunity persistence and immunogenicity after booster immunization of live attenuated varicella vaccines .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects C0001-C0400 except C0243 received 1 dose of booster immunization 1 year after primary immunization.
Biological: Investigational live attenuated varicella vaccine
Subjects C0401-C0800 except C0556 received 1 dose of booster immunization 2 years after primary immunization.
Biological: Investigational live attenuated varicella vaccine
Subjects C0801-C1197 received 1 dose of booster immunization 3 years after primary immunization.
Biological: Investigational live attenuated varicella vaccine
The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Immunogenicity index-seroconversion rate of antibody
seroconversion rates of antibody 1 year after primary immunization
Time frame: 1 year after primary immunization
Immunogenicity index-seroconversion rate of antibody
seroconversion rates of antibody 2 years after primary immunization
Time frame: 2 years after primary immunization
Immunogenicity index-seroconversion rate of antibody
seroconversion rates of antibody 3 years after primary immunization
Time frame: 3 years after primary immunization
Immunogenicity index-Seroconversion rate of antibody
Seroconversion rate of the neutralizing antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Immunogenicity index-seropositivity rate of antibody
Seropositivity rate of antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Immunogenicity index-Seropositivity rate of antibody
Seropositivity rate of antibody before booster immunization
Time frame: Before the booster dose immunization
Immunogenicity index-GMT of the antibody
GMT of the antibody before booster immunization
Time frame: Before the booster dose immunization
Immunogenicity index- GMT of the antibody
GMT of the antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Immunogenicity index- GMI of the antibody
GMI of the antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Safety index-Incidence of solicited local or systemic AE
Incidence of solicited local or systemic AE within 14 days after vaccination
Time frame: within 14 days after vaccination
Safety index-Incidence of local or systemic AE
Incidence of local or systemic AE within 30 days after vaccination
Time frame: within 30 days after vaccination
Safety index-Incidence of SAE
Incidence of SAE within 30 days after vaccination
Time frame: within 30 days after vaccination
Ran from Jul 2018 to primary completion in Aug 2018, 1 month.
Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 1 month is below that.
Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine
Sinovac (Dalian) Vaccine Technology Co., Ltd. →